fast Download PDF Now- 20262029 pipeline snapshot: Novo Nordisk CagriSema (GLP-1 + amylin) Filing 2026 Lilly Orforglipron (oral GLP-1) + Retatrutide (triple agonist) Launch window 20262027 Amgen Maritide (GLP-1 + GIP) 20272028 target BI / Zealand Survodutide (GLP-1 + glucagon) 2027 Altimmune Pemvidutide (GLP-1 + glucagon) 2027 Roche CT-388 / Petrelintide possible 2029 And one notable miss: Pfizer Danuglipron discontinued Clear trend: Single GLP-1 dual triple agonists Competition is shifting from: Who has a GLP-1? to Who has the most effective combination biology? Execution risk is still real but the bar for efficacy is moving quickly
Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Pilitsi E, et al
CJC-1295 is not FDA approved for general medical use
Research shows that GLP-1 medications paired with growth hormone-releasing peptides like Sermorelin can help preserve muscle mass during weight loss
(36464132) Circulating oral hypoglycemic agent : Mayo Clinic offers a screening test for hypoglycemic agents in the serum
Vitamin B12 deficiency can cause pernicious anemia, fatigue, and nerve damage
